X

Trial Profile

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients with Symptomatic Generalized Myasthenia Gravis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemdisiran (Primary) ; Pozelimab (Primary)
Indications Myasthenia gravis
Focus Registrational; Therapeutic Use
Acronyms NIMBLE
Sponsors Regeneron Pharmaceuticals

Most Recent Events

28 Jun 2024 Planned primary completion date changed from 29 Aug 2025 to 21 May 2025.
07 Mar 2024 Planned End Date changed from 1 May 2027 to 23 Mar 2028.
07 Mar 2024 Planned primary completion date changed from 14 Aug 2024 to 29 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com